• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Nuwellis Inc.

    8/2/24 4:12:11 PM ET
    $NUWE
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NUWE alert in real time by email
    SC 13G 1 ea0210477-13gintra_nuwellis.htm SCHEDULE 13G

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No.     )*

     

    Nuwellis, Inc.

     

    (Name of Issuer)

     

    Common stock, par value $0.0001 per share

     

    (Title of Class of Securities)

     

    67113Y405

    (CUSIP Number)

     

    July 24, 2024

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    a.☐ Rule 13d-1(b)
    b.☒ Rule 13d-1(c)
    c.☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

    Page 1 of 8

     

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Mitchell P. Kopin
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b) ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    58,888
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    58,888
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    58,888 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 2 of 8

     

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Daniel B. Asher
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b) ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    United States of America
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    58,888
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    58,888
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    58,888 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    IN; HC

     

    Page 3 of 8

     

     

    CUSIP No. 67113Y405

     

    1. Names of Reporting Persons.

    Intracoastal Capital LLC
    2. Check the Appropriate Box if a Member of a Group (See Instructions)

    (a) ☐
    (b) ☐
    3.

    SEC Use Only

     

     

    4.

    Citizenship or Place of Organization

     

     

    Delaware
    Number of
    Shares Beneficially
    Owned by Each
    Reporting
    Person With:
    5. 

    Sole Voting Power

     

    0
    6.

    Shared Voting Power

     

    58,888
    7.

    Sole Dispositive Power

     

    0
    8.

    Shared Dispositive Power

     

    58,888
    9.

    Aggregate Amount Beneficially Owned by Each Reporting Person

     

     

    58,888 (see Item 4)

    10.

    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

     

     

    11.

    Percent of Class Represented by Amount in Row (9)

     

     

    4.99% (see Item 4)

    12. Type of Reporting Person (See Instructions)

    OO

     

    Page 4 of 8

     

     

    Item 1.

     

    (a)Name of Issuer

     

    Nuwellis, Inc. (the “Issuer”)

     

    (b)Address of Issuer’s Principal Executive Offices

     

    12988 Valley View Road

    Eden Prairie, Minnesota 55344

     

    Item 2.

     

    (a)Name of Person Filing

     

    (b)Address of Principal Business Office or, if none, Residence

     

    (c)Citizenship

     

    This Schedule 13G is being filed on behalf of (i) Mitchell P. Kopin, an individual who is a citizen of the United States of America (“Mr. Kopin”), (ii) Daniel B. Asher, an individual who is a citizen of the United States of America (“Mr. Asher”) and (iii) Intracoastal Capital LLC, a Delaware limited liability company (“Intracoastal” and together with Mr. Kopin and Mr. Asher, collectively the “Reporting Persons”).

     

    The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.

     

    The principal business office of Mr. Kopin and Intracoastal is 245 Palm Trail, Delray Beach, Florida 33483.

     

    The principal business office of Mr. Asher is 111 W. Jackson Boulevard, Suite 2000, Chicago, Illinois 60604.

     

    (d)Title of Class of Securities

     

    Common stock, par value $0.0001 per share, of the Issuer (the “Common Stock”).

     

    (e)CUSIP Number

     

    67113Y405

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    Not applicable.

     

    Page 5 of 8

     

     

    Item 4.Ownership.

     

    (a)and (b):

     

    (i) Immediately following the execution of the Securities Purchase Agreement with the Issuer on July 24, 2024 (the “SPA”) (as disclosed in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on July 25, 2024), each of the Reporting Persons may have been deemed to have beneficial ownership of 51,887 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 7.4% of the Common Stock, based on (1) 651,911 shares of Common Stock outstanding as of July 24, 2024 as reported by the Issuer, plus (2) 51,887 shares of Common Stock to be issued to Intracoastal at the closing of the transaction contemplated by the SPA. The foregoing excludes (I) 103,774 shares of Common Stock issuable upon exercise of a warrant to be issued to Intracoastal at the closing of the transaction contemplated by the SPA (“Intracoastal Warrant 1”) because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock, (II) 847 shares of Common Stock issuable upon exercise of a warrant held by Intracoastal (“Intracoastal Warrant 2”) because Intracoastal Warrant 2 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 2 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (III) 160,946 shares of Common Stock issuable upon exercise of a second warrant held by Intracoastal (“Intracoastal Warrant 3”) because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 317,454 shares of Common Stock.

     

    (ii) As of the close of business on August 2, 2024, each of the Reporting Persons may have been deemed to have beneficial ownership of 58,888 shares of Common Stock, which consisted of (i) 847 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2 and (ii) 58,041 shares of Common Stock issuable upon exercise of Intracoastal Warrant 2, and all such shares of Common Stock in the aggregate represent beneficial ownership of approximately 4.99% of the Common Stock, based on (1) 651,911 shares of Common Stock outstanding as of July 24, 2024 as reported by the Issuer, plus (2) 469,340 shares of Common Stock issued at the closing of the transaction contemplated by the SPA, (3) 847 shares of Common Stock issued to Intracoastal upon exercise of Intracoastal Warrant 2 and (4) 58,041 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1. The foregoing excludes (I) 45,733 shares of Common Stock issuable upon exercise of Intracoastal Warrant 1 because Intracoastal Warrant 1 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 1 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock and (II) 250,994 shares of Common Stock issuable upon exercise of Intracoastal Warrant 3 because Intracoastal Warrant 3 contains a blocker provision under which the holder thereof does not have the right to exercise Intracoastal Warrant 3 to the extent (but only to the extent) that such exercise would result in beneficial ownership by the holder thereof, together with the holder’s affiliates, and any other persons acting as a group together with the holder or any of the holder’s affiliates, of more than 4.99% of the Common Stock. Without such blocker provisions, each of the Reporting Persons may have been deemed to have beneficial ownership of 355,615 shares of Common Stock.

     

    Page 6 of 8

     

     

    (c)Number of shares as to which each Reporting Person has:

     

    (i)Sole power to vote or to direct the vote:            0             .

     

    (ii)Shared power to vote or to direct the vote:            58,888             .

     

    (iii)Sole power to dispose or to direct the disposition of            0            .

     

    (iv)Shared power to dispose or to direct the disposition of            58,888            .

     

    Item 5.Ownership of Five Percent or Less of a Class

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following þ.

     

    Item 6.Ownership of More than Five Percent on Behalf of Another Person.

     

    Not applicable.

     

    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certification

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

    Page 7 of 8

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Date: August 2, 2024

     

      /s/ Mitchell P. Kopin
      Mitchell P. Kopin
       
      /s/ Daniel B. Asher
      Daniel B. Asher

     

      Intracoastal Capital LLC
         
      By: /s/ Mitchell P. Kopin
        Mitchell P. Kopin, Manager

     

    Page 8 of 8

    Get the next $NUWE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NUWE

    DatePrice TargetRatingAnalyst
    7/29/2024$17.00Buy
    ROTH MKM
    More analyst ratings

    $NUWE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/30/24 4:11:06 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      8/2/24 4:12:11 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by Nuwellis Inc.

      SC 13G - Nuwellis, Inc. (0001506492) (Subject)

      5/6/24 4:01:02 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Nuwellis Expands Aquadex® for Pediatric Fluid Management to Two New Hospital Systems

      MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced a meaningful step forward for children facing fluid overload with the recent expansion of its Aquadex SmartFlow® therapy into two additional pediatric centers across the Southeastern United States. The company now has 47 pediatric centers that have adopted Aquadex therapy as part of their fluid management approach. Even in well-managed care settings, fluid overload can be a turning point in recovery for pediatric patients—who often have a narrow margin for error. When alternative therapies fall

      5/8/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Expands IP Portfolio with Patent That Reduces Clinical Burden, Preserves Precision

      WHOWHATWHEREWHENWHYNuwellis, Inc.Issuance of U.S. Patent No. 12,280,007.United States Patent and Trademark OfficeApril 22, 2025To protect a novel self-emptying fluid bag design that improves nursing workflow while maintaining system accuracy. MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on fluid management solutions for patients with fluid overload, today announced the issuance of U.S. Patent No. 12,280,007 by the U.S. Patent and Trademark Office. The newly granted patent covers a fluid bag design that passively drains once full—reducing the need for manual intervention by clinical staff while preserving the system's pre

      4/24/25 7:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

      MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a

      4/22/25 4:04:59 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Financials

    Live finance-specific insights

    See more
    • Nuwellis, Inc. To Report First Quarter 2025 Financial Results on May 13, 2025

      MINNEAPOLIS, April 22, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the first quarter 2025 on May 13, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-579-2543 (U.S) or 1-785-424-1789 (international) and using the conference ID: NUWEQ1. An a

      4/22/25 4:04:59 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. Announces Fourth Quarter and Full Year 2024 Financial Results

      MINNEAPOLIS, March 11, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical device company focused on transforming the lives of people with fluid overload, today reported financial results for the fourth quarter and full year ended December 31, 2024. Recent Highlights: CMS four-fold payment increase to $1,639 for Aquadex Ultrafiltration Therapy in the outpatient setting effective January 1, 2025.New data published in JACC: Heart Failure showed Aquadex ultrafiltration reduced heart failure events by 60% compared to IV diuretics.Full year operating cost reduction of $5.9 million, or 26%, compared to the pr

      3/11/25 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis, Inc. To Report Fourth Quarter and Full Year 2024 Financial Results on March 11, 2025

      MINNEAPOLIS, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a commercial-stage medical technology company focused on transforming the lives of people with fluid overload, today announced that it will release financial results for the fourth quarter and full year 2024 on March 11, 2025. Nuwellis will host a conference call and webcast at 9:00 AM ET to discuss its financial results and provide a general business update. To access the live webcast, please visit the Investors page of the Nuwellis website at https://ir.nuwellis.com. Alternatively, you may access the live conference call by dialing 1-800-245-3047 (U.S) or 1-203-518-9765 (international) and using the conference

      2/18/25 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Nuwellis with a new price target

      ROTH MKM initiated coverage of Nuwellis with a rating of Buy and set a new price target of $17.00

      7/29/24 7:42:07 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Leadership Updates

    Live Leadership Updates

    See more
    • Nuwellis Announces Retirement of Nestor Jaramillo, Jr. as President and CEO

      MINNEAPOLIS, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, announced today that Nestor Jaramillo, Jr. retired as President and Chief Executive Officer and as a director of the company, effective February 18, 2025. John Erb, who currently serves as Chairman of the company's Board of Directors, assumed the role of Interim President and Chief Executive Officer and assumed all of the duties formerly performed by Mr. Jaramillo. Nuwellis intends to retain an executive search firm to assist in identifying a permanent CEO. Mr. Erb, stated, "Nestor has been with the company for nearly si

      2/24/25 4:05:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces Board of Directors Transition

      MINNEAPOLIS, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of people with fluid overload, today announced the appointment of Dave McDonald and Archelle Georgiou, MD, to its board of directors, effective November 1, 2023. "With decades of experience and leadership in their respective fields, we welcome Dave and Archelle to our board. Dave's significant experience in finance and strategy will provide key insights to our board as we advance our growth and expansion initiatives. In turn, our board will benefit from perspectives gained from Archelle's healthcare policy, clinical, and patient education experience

      11/1/23 8:00:00 AM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors

      MINNEAPOLIS, June 05, 2023 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (NASDAQ:NUWE), a medical technology company focused on transforming the lives of patients suffering from fluid overload, today announced that Mike McCormick has been appointed to the company's Board of Directors. Mr. McCormick's vast experience includes more than 25 years of service in the medical device industry through varying leadership roles for several private and publicly traded companies. Mr. McCormick will also serve as Lead Independent Director and serve as a member of the Audit Committee and as Chair of the Nominating and Corporate Governance Committee of the Board. "We are delighted to welcome Mike to Nuwellis' Board

      6/5/23 4:15:00 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    SEC Filings

    See more
    • SEC Form DEFR14A filed by Nuwellis Inc.

      DEFR14A - Nuwellis, Inc. (0001506492) (Filer)

      5/9/25 5:15:32 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form DEF 14A filed by Nuwellis Inc.

      DEF 14A - Nuwellis, Inc. (0001506492) (Filer)

      4/14/25 4:05:22 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Nuwellis Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Nuwellis, Inc. (0001506492) (Filer)

      4/3/25 5:07:53 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NUWE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Mccormick Michael Kendrick

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:25:39 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Mcdonald David

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:21:51 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Feldshon Archelle Georgiou

      4 - Nuwellis, Inc. (0001506492) (Issuer)

      1/4/24 4:16:08 PM ET
      $NUWE
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care